3 High Volume Diagnostics Laboratory, Multi Speciality Hospitals Operator and Biopharma Technology Services Firm Stocks With a Strong Future Roadmap: Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene

Lab, hospital and pharma services stocks offer a focused view of a sector where demand keeps widening. Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene cover a high volume diagnostics laboratory, a multi speciality hospitals operator and a biopharma technology services firm.

This list covers three lab, hospital and pharma services stocks with complete current figures: Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene. Every figure comes from the latest reported financials and the 29 October 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Lab, Hospital and Pharma Services Stocks?

Lab, hospital and pharma services stocks are listed companies that run a central testing laboratory with a wide partner network, operate hospitals with strong maternity, child care and surgery services and help drug and device makers with commercial, medical and regulatory work. Their earnings depend on test volumes, patient numbers and client contracts.

Lab, Hospital and Pharma Services Stocks at a Glance

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing lab, hospital and pharma services stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Lab, Hospital and Pharma Services Stocks Have a Strong Roadmap in India?

Lab, hospital and pharma services stocks have a strong roadmap in India because rising health awareness, wider screening and insurance cover and growing use of data in drug development keep widening the market for these healthcare companies.

• Preventive care. More people take regular health tests.
• Hospital demand. Families seek trusted maternity and surgical care.
• Pharma services. Drug makers outsource commercial work.

Why Thyrocare Technologies Features Among These Lab, Hospital and Pharma Services Stocks

Among the lab, hospital and pharma services stocks on this list, Thyrocare Technologies runs a centralised, high-volume testing laboratory in Navi Mumbai and collects samples through a wide partner network of diagnostic centres, pharmacies and franchisees across India.

The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P/E of 42.6, below the industry P/E of 59.6.

Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore.

Roadmap: The centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.

What to watch: Track growth in test volume per day and the share of revenue from preventive health packages.

Why Jupiter Life Line Hospitals Features Among These Lab, Hospital and Pharma Services Stocks

Among the patient care and life science shares on this list, Jupiter Life Line Hospitals runs multi-speciality hospitals in Pune, Thane and Indore, with strong services in maternity, child care, critical care and advanced surgery.

Revenue rose from Rs 737 crore in FY22 to Rs 1,542 crore in FY26, a compound annual growth rate of 20.3%. Net profit grew from Rs 51.1 crore in FY22 to Rs 194 crore in FY26, which works out to a compound annual growth rate of 39.6%.

The company has a return on equity of 11.4%, a debt to equity ratio of 0.41 and a market capitalisation of Rs 8,007 crore. The stock trades at a P/E of 42.6, below the industry P/E of 58.4.

Roadmap: The company is adding beds and expanding to new locations while growing specialist services. Rising demand for quality private care in its cities supports occupancy.

What to watch: Follow bed additions, occupancy levels and revenue per occupied bed.

Why Indegene Features Among These Lab, Hospital and Pharma Services Stocks

Among the three companies on this list, Indegene is a Bengaluru-based healthcare technology and services company that helps biopharma and medical technology firms with commercial, medical and regulatory work using data and technology.

In the June 2026 quarter, revenue grew 39.5% year on year to Rs 1,092 crore. Revenue rose from Rs 1,690 crore in FY22 to Rs 3,582 crore in FY26, a compound annual growth rate of 20.7%.

Net profit grew from Rs 163 crore in FY22 to Rs 401 crore in FY26, which works out to a compound annual growth rate of 25.3%. The company has a return on equity of 12.8%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 14,454 crore. The stock trades at a P/E of 36.0, below the industry P/E of 59.2.

Roadmap: The company is widening its digital and artificial intelligence services for life sciences clients and adding new customers across drug and device makers. Multi-year contracts with global clients support recurring revenue.

What to watch: Monitor client additions, platform adoption and growth in artificial intelligence services.

Thyrocare Technologies vs Jupiter Life Line Hospitals vs Indegene on Key Financials

The table below sets the three lab, hospital and pharma services stocks side by side on revenue, profit and margin, using reported figures.

Thyrocare Technologies posts the highest return on equity in this group at 27.9%. Indegene combines the largest FY26 revenue at Rs 3,582 crore with the fastest revenue growth, a 20.7% compound annual rate. A useful habit with lab, hospital and pharma services stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Lab, Hospital and Pharma Services Stocks

Every theme carries risks that deserve a check before any decision. For these lab, hospital and pharma services stocks, the main points are: Long-term patient care and life science shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Test volumes. Footfall and test mix can vary with seasons.
• Capacity ramp up. New hospitals take time to fill beds and reach full returns.
• Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter lab, hospital and pharma services stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Lab, Hospital and Pharma Services Stocks

Lab, hospital and pharma services stocks reward patient research into demand, execution and financial strength. Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene each have a clear plan to grow. Based on the 29 October 2026 close, Thyrocare Technologies trades at Rs 515.5, Jupiter Life Line Hospitals at Rs 260.1 and Indegene at Rs 593.45. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these lab, hospital and pharma services stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track lab, hospital and pharma services stocks, set price alerts and get research-backed stock ideas.

What are lab, hospital and pharma services stocks?

Ans. Lab, hospital and pharma services stocks are listed companies that run a central testing laboratory with a wide partner network, operate hospitals with strong maternity, child care and surgery services and help drug and device makers with commercial, medical and regulatory work. Their earnings depend on test volumes, patient numbers and client contracts. This list looks at three of them, Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene, using reported FY22 to FY26 financials and the 29 October 2026 closing prices.

Which lab, hospital and pharma services stocks are covered in this list?

Ans. This list covers Thyrocare Technologies, Jupiter Life Line Hospitals and Indegene. Based on the 29 October 2026 close, Thyrocare Technologies traded at Rs 515.5, Jupiter Life Line Hospitals at Rs 260.1 and Indegene at Rs 593.45. Their return on equity ranges from 11.4% to 27.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.2% to 20.7%.

Why do lab, hospital and pharma services stocks have a strong future roadmap in India?

Ans. Lab, hospital and pharma services stocks have a strong roadmap in India because rising health awareness, wider screening and insurance cover and growing use of data in drug development keep widening the market for these healthcare companies. The main drivers are as follows. Preventive care. More people take regular health tests. Hospital demand. Families seek trusted maternity and surgical care. Pharma services. Drug makers outsource commercial work. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Thyrocare Technologies performed financially?

Ans. Revenue rose from Rs 618 crore in FY22 to Rs 846 crore in FY26, a compound annual growth rate of 8.2%. Net profit grew from Rs 64.4 crore in FY23 to Rs 163 crore in FY26, which works out to a compound annual growth rate of 36.3%. In the June 2026 quarter, revenue grew 23.5% year on year to Rs 244 crore, while net profit rose 34.1% to Rs 51.3 crore. The company has a return on equity of 27.9%, a debt to equity ratio of 0.09 and a market capitalisation of Rs 7,501 crore. The stock trades at a P/E of 42.6, below the industry P/E of 59.6. Looking ahead, the centralised model gives it a low unit cost per test, and the company is adding wellness and preventive health packages along with a growing share of direct-to-consumer bookings. Its partner-led channel lets it scale volumes without building its own collection centres.

How has Jupiter Life Line Hospitals performed financially?

Ans. Revenue rose from Rs 737 crore in FY22 to Rs 1,542 crore in FY26, a compound annual growth rate of 20.3%. Net profit grew from Rs 51.1 crore in FY22 to Rs 194 crore in FY26, which works out to a compound annual growth rate of 39.6%. The company has a return on equity of 11.4%, a debt to equity ratio of 0.41 and a market capitalisation of Rs 8,007 crore. The stock trades at a P/E of 42.6, below the industry P/E of 58.4. Looking ahead, the company is adding beds and expanding to new locations while growing specialist services. Rising demand for quality private care in its cities supports occupancy.

How has Indegene performed financially?

Ans. Revenue rose from Rs 1,690 crore in FY22 to Rs 3,582 crore in FY26, a compound annual growth rate of 20.7%. Net profit grew from Rs 163 crore in FY22 to Rs 401 crore in FY26, which works out to a compound annual growth rate of 25.3%. In the June 2026 quarter, revenue grew 39.5% year on year to Rs 1,092 crore. The company has a return on equity of 12.8%, a debt to equity ratio of 0.05 and a market capitalisation of Rs 14,454 crore. The stock trades at a P/E of 36.0, below the industry P/E of 59.2. Looking ahead, the company is widening its digital and artificial intelligence services for life sciences clients and adding new customers across drug and device makers. Multi-year contracts with global clients support recurring revenue.

What risks should investors check before buying lab, hospital and pharma services stocks?

Ans. Investors should check a few risks before buying lab, hospital and pharma services stocks. Test volumes. Footfall and test mix can vary with seasons. Capacity ramp up. New hospitals take time to fill beds and reach full returns. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of lab, hospital and pharma services stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 29 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.